The pharmacokinetics and metabolism of ifosfamide during bolus and infusional administration: A randomized cross-over study

British Journal of Cancer

Volumn 77, Issue 6, 1998, Pages 978-984

  Singer, J M ^a   Hartley, J M ^a   Brennan, C ^a   Nicholson, P W ^a   Souhami, R L ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Dexamethasone; Ifosfamide; Pharmacokinetics; Schedule; Thin layer chromatography

Indexed keywords

DEXAMETHASONE; DRUG METABOLITE; IFOSFAMIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BOLUS INJECTION; BONE MARROW TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG URINE LEVEL; EWING SARCOMA; FEMALE; HUMAN; MALE; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOFT TISSUE SARCOMA; THIN LAYER CHROMATOGRAPHY;

EID: 0031888502     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.161     Document Type: Article

References (29)

1. Allen LM and Creaven PJ (1972) In vitro activation of isophosphamide (NSC-109724), a new oxazaphosphorine, by rat liver microsomes. Cancer Chemoth Rep 56: 603-610
2. Allen LM and Creaven PJ (1975) Human pharmacokinetic model for isophosphamide (NSC-109724). Cancer Chemother Rep 59: 877-882
3. Anderson H, Hopwood P, Prendiville J, Radford JA, Thatcher N and Ashcroft L (1993) A randomised study of bolus vs continuous pump infusion of ifosfamide and doxorubicin with oral etoposide for small cell lung cancer. Br J Cancer 67: 1385-1390
4. Boddy AV and Idle JR (1992) Combined thin-layer chromatography-photography-densitometry for the quantification of ifosfamide and its principal metabolites in urine, cerebrospinal fluid and plasma. J Chromatogr 575: 137-142
5. Boddy AV, Yule SM, Wyllie R, Price L, Pearson ADJ and Idle JR (1993) Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children. Cancer Res 53: 3758-3764
6. Boddy AV, Proctor M, Simmonds D, Lind MJ and Idle JR (1945a). Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients. Eur J Cancer 31A: 69-71
7. Boddy AV, Yule SM, Wyllie R, Price L, Pearson ADJ and Idle JR (1995b) Comparison of continuous infusion and bolus administration of ifosfamide in children. Eur J Cancer 31A: 785-790
8. Boddy AV, Yule SM, Wyllie R, Price L, Idle JR (1996) Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repealed administration. Cancer Chemother Pharmacol 32: 147-154
9. Brade WP, Herdrich K and Varini M (1985) Ifosfamide - pharmacology, safety and therapeutic potential. Cancer Treat Rev 12 (suppl. A): 1-47
10. Brock N (1983) The oxazaphosphorines. Cancer Treat Rev 10: 3-15
11. Brock N and Hohorst HJ (1963) Uber die Aktivierung von cyclophosphamid in vivo und in vitro. Arzneim Forsch 13: 1021-1031
12. Creaven PJ, Allen LM, Alford DA and Cohen MH (1974) Clinical pharmacology of isophosphamide. Clin Pharmacol Ther 16: 77-86
13. Hartley JM, Hansen L, Harland SJ, Nicholson PW, Pasini F and Souhami RL (1994) Metabolism of ifosfamide during a 3 day infusion. Br J Cancer 69: 931-936
14. Kaijser GP, Korst A, Beijnen JH, Bult A and Underberg WJM (1993) The analysis of ifosfamide and its metabolites (review). Anticacer Res 13: 1311-1324
15. Kaijser GP, Beijnen JH, Bult A and Underberg WJM (1994) Ifosfamide metabolism and pharmacokinetics (review). Anticancer Res 14: 517-532
16. Klein OH, Wickramanyake PD, Christian E and Coerper C (1984) Therapeutic effects of single push or fractionated injections or continuous infusions of oxazaphosphorines (cyclophosphamide, ifosfamide, ASTA Z7557). Cancer 54: 1193-1203
17. Kurowski V and Wagner T (1993) Comparative pharmacokinetics of ifosfamide. 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. Cancer Chemother Pharmacol 33: 36-42
18. Lind MJ, Margison JM, Cerny T, Thatcher N and Wilkinson PM (1989a). Comparative pharmacokinetics and alkyating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma. Cancer Res 49: 753-757
19. Lind MJ, Margison JM, Cerny T, Thatcher N and Wilkinson PM (1989b). Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution. Cancer Chemother Pharmacol 25: 139-142
20. Lind MJ, Roberts HL, Thatcher N and Idle JR (1990) The effect of route of administration and fractionation of dose on the metabolism of ifosfamide. Cancer Chemother Pharmcol 26: 105-111
21. Morgan LR, Harrison JE, Hawke JE, Hunter HL, Costanzi JJ, Plotkin D, Tucker WG and Worrall PM (1982) Toxicity of single- vs. fractionated-dose ifosfamide in non-small cell lung cancer: a multi-center study. Sem Oncol 9: 66-70
22. Murray M, Butler AM and Stupans I (1994). Competitive inhibition of human liver microsomal cytochrome P450-dependent steroid 6β-hydroxylation activity by cyclophosphamide and ifosfamide in vitro. J Pharmacol Exp Ther 270: 645-649
23. Nelson RL, Allen LM and Creaven PJ (1976) Pharmacokinetics of divided-dose ifosfamide. Clin Pharmacol Ther 19: 365-370
24. Rodriguez V, Bodley GP, Freireich EJ, McCredie KB, McKelvey EM and Tashima CK (1976) Reduction of ifosfamide toxicity using dose fracfionation. Cancer Res 36: 2945-2948
25. Ruzicka JA and Ruenitz PC (1992) Cytochrome P-450-mediated N-dechloroethylation of cyclophosphamide and ifosfamide in the rat. Drug Metab 20: 770-772
26. Wagner T (1994) Ifosfamide clinical pharmacokinetics. Clin Pharm 26: 439-456
27. Walker D, Flinois J-P, Monkman SC, Beloc C, Boddy AV, Cholerton S, Daly AK, Lind MJ, Pearson, ADJ, Beaune PH and Idle JR (1994) Identification of the major human hepatic cytochrome P450 involved in activation and n-dechloroethylation of Ifosfamide. Biochem Pharmacol 47: 1157-1163
28. Webor GF and Waxman DJ (1993) Activation of the anti-cancer drug ifosfamide by rat liver microsomal P450 enzymes. Biochem Pharmacol 45: 1685-1694
29. Yule SM, Boddy AV, Cole M, Price L, Wyllie R, Tasso MJ, Pearson DJ and Idle JR (1995) Cyclophosphamide metabolism in children. Cancer Res 55: 803-809